You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Filamin A antibody (ab51217)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Filamin A antibody
See all Filamin A products (10) ...

Description

Rabbit polyclonal to Filamin A

Specificity

This antibody detects endogenous levels of total Filamin A protein.

Tested applications

WB, ELISA, ICCmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

A synthesized non-phosphopeptide derived from human Filamin A around the phosphorylation site of serine 2152 (A-P-SP-V-A).

Positive control

Extracts of 293 cells.

Properties

Form

Liquid

Storage instructions

Store at -20°C. Stable for 12 months at -20°C

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Purification notes

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Clonality

Polyclonal

Isotype

IgG

  • Western blot - Filamin A antibody (ab51217)Western blot - Filamin A antibody (ab51217) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab51217 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.

Tissue specificity

Ubiquitous.

Involvement in disease

Defects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period.
Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood.
Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum.
Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects.
Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies.
Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull.
Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion.
Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation.
Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females.
Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets.

Sequence similarities

Belongs to the filamin family.
Contains 1 actin-binding domain.
Contains 2 CH (calponin-homology) domains.
Contains 24 filamin repeats.

Domain

Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.

Post-translational
modifications

Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation.
The N-terminus is blocked.

Cellular localization

Cytoplasm > cell cortex. Cytoplasm > cytoskeleton.

Target information above from: UniProt accessionP21333 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • ABP 280 antibody
  • ABP-280 antibody
  • Actin-binding protein 280 antibody
  • Alpha filamin antibody
  • Alpha-filamin antibody
  • APBX antibody
  • Endothelial actin binding protein antibody
  • Endothelial actin-binding protein antibody
  • Filamin 1 antibody
  • Filamin A antibody
  • Filamin-1 antibody
  • Filamin-A antibody
  • FLN antibody
  • FLN-A antibody
  • FLN1 antibody
  • FLNA antibody
  • FLNA_HUMAN antibody
  • MNS antibody
  • NHBP antibody
  • Non muscle filamin antibody
  • Non-muscle filamin antibody
  • OPD antibody
  • OPD1 antibody
  • OPD2 antibody
see all

Anti-Filamin A antibody images:

  Western blot - Filamin A antibody (ab51217)

Western blot - Filamin A antibody (ab51217)

All lanes : Anti-Filamin A antibody (ab51217) at 1/300 dilution

Lane 1 : Extracts of 293 cells treated with EGF (200ng/ml, 5mins).
Lane 2 : Extracts of 293 cells treated with EGF (200ng/ml, 5mins) and peptide.


Predicted band size : 281 kDa
Observed band size : 281 kDa

References for Anti-Filamin A antibody (ab51217)

This product has been referenced in:

  • Sayner SLet al. Filamin A is a phosphorylation target of membrane but not cytosolic adenylyl cyclase activity. Am J Physiol Lung Cell Mol Physiol 301:L117-24 (2011). WB, ICC/IF; Rat.Read more (PubMed: 21478251) »
  • Cooper Jet al. Filamin a protein interacts with human immunodeficiency virus type 1 gag protein and contributes to productive particle assembly. J Biol Chem 286:28498-510 (2011). Flow Cyt; Human.Read more (PubMed: 21705339) »

See all 2 publications for this product

Publishing research using ab51217? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"